Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia (CEPHEUS)

AstraZeneca

Status: Completed

Conditions: Hypercholesterolemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01604733

NIS-EG-CRE-2010/01

Details and patient eligibility

About

Study objective is to evaluate the level of control of hypercholesterolemia in Egypt in patients taking lipid lowering agents for at least 3 months ( with no drug change or dose amendment for a minimum of 6 weeks).

Full description

Centralized Pan-Middle East Survey on the Undertreatment of Hypercholesterolemia

Enrollment: 1,000 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years and above on current lipid lowering drug for at least 3 months with no dose change for a minimum of 6 weeks
• Subject must provide informed consent and comply with the survey procedures

Exclusion criteria

• Less than 18 years less than 3 months on antidyslipidemic agent Subjects who are unwilling or unable to provide informed consent

Trial design

1,000 participants in 1 patient group

HYPERCHOLESTEROLEMIC PATIENTS